-
Bill Ackman Slams Subsidies For Contributing To $37 Trillion National Debt, Hails Trump's Drug Price Order
Monday, May 12, 2025 - 2:24am | 782Read More...Billionaire investor and the CEO of Pershing Square, Bill Ackman, flagged the contribution of various subsidies to the mounting U.S. debt and appreciated President Donald Trump for proposing an order to cut the drug prices, quoting his earlier suggestion. What Happened: In an X post, Ackman...
-
Poseida Shares Tank 34.5% As Prostate Cancer Drug Trial Halted After Patient's Death
Monday, August 17, 2020 - 11:33pm | 256Read More...Poseida Therapeutics Inc. (NASDAQ: PSTX) stock dropped about 34.5% in the after-hours trading on Monday, after a patient died in a prostate cancer drug trial, according to a filing the company made with the United States Securities and Exchange Commission. What Happened The trial was carried out in...
-
Drugs War: Europe under siege as crime syndicates piggyback supply chains (With Video)
Monday, December 2, 2019 - 12:39pm | 1042Read More...Maritime, air and overland trade routes into Europe are being piggybacked by criminal gangs deploying the latest digital supply chain technologies to help meet mushrooming demand for illegal drugs across the European Union (EU), according to a major new report examining the continent's illicit...
-
Botox Competition Spurs Argus To Downgrade Allergan
Thursday, December 7, 2017 - 1:18pm | 446Read More...Shares of Allergan plc Ordinary Shares (NYSE: AGN) continue trading near their multi year low of $160.07, with many investors concerned with a competitive environment that will intensify in the coming years. The Analyst Argus' David Toung downgraded Allergan's stock rating from Buy to...
-
Bloomberg: GlaxoSmithKline, Qualcomm To Jointly Develop Medical Technology
Wednesday, January 20, 2016 - 2:34pm | 161Read More...According to Bloomberg, GlaxoSmithKline plc (ADR) (NYSE: GSK) and QUALCOMM, Inc. (NASDAQ: QCOM) are discussing ways to combine both companies expertise and create advances in medical technology. Bloomberg, citing "people with knowledge of the matter," noted that GlaxoSmithKline isn...
-
Investment Fund Manager: GlaxoSmithKline Should Be Broken Up, Shares Tick Higher
Friday, January 8, 2016 - 12:57pm | 223Read More...Neil Woodford is the founder of Woodford Investment Management, an asset management company with £12.5bn of assets under management. Woodford is considered one of the Britain's most successful and influential investors and recently shared his thoughts of drug companies with the BBC. Woodford told...
-
Big Drug Cos. Are Slackers in Emerging Mkts.
Wednesday, March 17, 2010 - 2:43pm | 209Read More...The leading drug makers aren’t doing enough to gain market share in emerging markets, according to a report that was issued by IMS Health, a research company based in Norwalk, Conn., that tracks prescriptions and other data on drug sales. That’s according to an article in today’s New York Times....
-
Merck leads drug stocks up
Wednesday, January 13, 2010 - 3:01pm | 199Read More...Shares of pharmaceutical giant Merck & Co. (NYSE: MRK) were up after analysts at Credit Suisse upgraded the stock rating from a neutral to an outperform and raised the target price from $35 to $47. Credit Suisse cited the many promising products in Merck's pipeline. Merck Chief Executive...
